Literature DB >> 11026799

Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.

A T Goon1, S H Tan, L S Khoo, T Tan.   

Abstract

AIM OF STUDY: To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid.
METHODS: An open trial of 11 patients with bullous pemphigoid. Treatment was initiated with tetracycline 1.5-2 g/day and nicotinamide 1.5-2 g/day and gradually tapered down. Doxycycline was substituted for tetracycline in patients who could not tolerate tetracycline due to gastrointestinal side effects or headache.
RESULTS: 6 out of 11 patients achieved complete response (> 90% decrease in lesions) while another 2 had partial response (50-90% decrease in lesions).
CONCLUSION: Tetracycline/doxycycline and nicotinamide is a useful alternative treatment for localized bullous pemphigoid, especially in those whose concurrent medical illnesses preclude the use of systemic corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026799

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  3 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

3.  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Authors:  Hywel C Williams; Fenella Wojnarowska; Gudula Kirtschig; James Mason; Thomas R Godec; Enno Schmidt; Joanne R Chalmers; Margaret Childs; Shernaz Walton; Karen Harman; Anna Chapman; Diane Whitham; Andrew J Nunn
Journal:  Lancet       Date:  2017-03-06       Impact factor: 79.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.